Bris­tol My­er­s' Chi­na part­ner touts Phase 3 suc­cess for EGFRx­HER3 bis­pe­cif­ic ADC

Bris­tol My­ers Squibb’s for­ay in­to can­cer an­ti­body-drug con­ju­gates and bis­pecifics ap­pears to be bear­ing fruit.

Chi­nese start­up Biokin, which part­nered with Bris­tol My­ers through its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER